title: Combination antiretroviral therapy. Back to the future.
abstract: HIV causes chronic infection and is associated with persistent viral replication and a high viral mutation rate. It is an illusion to think that monotherapy with any antiretroviral agent will have a major and lasting impact on this disease. Monotherapy with antitubercular agents led to dramatic improvements in treatment, but the development of drug resistance meant that these improvements were of only short duration, and hence it was concluded that drugs should be combined. The response to the limited efficacy of nucleoside analogue monotherapy in HIV infection has in many instances been the stance that 'currently available antiretrovirals are no good; it is better not to treat'. In addition, regulatory insistence on clinical end-points has also hampered antiretroviral drug development. It is implied that antiretrovirals must be tested in populations with fairly advanced HIV infection, in whom the least success may be expected. The regulatory bind has also resulted in artificial and counterproductive treatment guidelines. Common sense and experience in infectious diseases dictate that treatment should hit hard and early. No study published thus far undermines the concept that early therapy is better than late therapy or that a tolerable combination of drugs with additive or synergistic anti-HIV activity is better than nucleoside monotherapy. Promising data have been generated in trials on combinations of zidovudine plus didanosine or zalcitabine; a combination of zidovudine and lamivudine (3TC) may be even more promising.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Academic Medical Centre, University of Amsterdam, The Netherlands.
authors.forename: J
authors.initials: J
authors.lastname: Lange
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000998:Antiviral Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D006801:Humans; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000998:Antiviral Agents